Radioligand therapy using lutetium (Lu-177) labelled PSMA (prostate specific membrane antigen)-targeted ligand

Radioligand therapy using lutetium (177-Lu) labelled prostate specific membrane antigen-targeted ligand (procedure)

procedure
£1.00

Supplier: uk-edition · SCTID 1853521000000101

Also known as (1)
  • Radioligand therapy using lutetium (177-Lu) labelled prostate specific membrane antigen-targeted ligand

Found in

Destructive procedure Nuclear medicine procedure

Related products

Ablation using fluoroscopic guidance
£1.00
Ablation using magnetic resonance imaging guidance
£1.00
Caesium 137 brachytherapy
£1.00
Californium 252 brachytherapy
£1.00
Carbon dioxide laser photocoagulation
£1.00
Cauterisation
£1.00
Chemosurgery
£1.00
Cobalt-60 therapy
£1.00
Crushing
£1.00
Cryotherapy
£1.00
CT guided ablation
£1.00
Destruction of lesion
£1.00
Destructive procedure by anatomic site
£1.00
Dynamic non-imaging isotope study
£1.00
Electrocoagulation with curettage
£1.00
Electrodesiccation
£1.00
Emulsification procedure
£1.00
External beam radiation therapy using carbon ions
£1.00
External beam radiation therapy with dual headed cobalt unit
£1.00
External beam radiation therapy with radioactive caesium
£1.00
Fragmentation procedure
£1.00
Fulguration
£1.00
Gold 198 therapy
£1.00
High intensity focused ultrasound ablation
£1.00
Basket
Total£0.00